Mesothelioma Clinical Trials

Below are two sample mesothelioma trials being conducted at New York Presbyterian Hospital. See their website for more information: http://cpmcnet.columbia.edu/dept/medicine/mesothelioma/index.html

ALIMTA and Cisplatin

Title: Open-Label Study of ALIMTA (pemetrexed) in Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma

Eligibility Requirements:

  • Histologically confirmed malignant pleural mesothelioma
  • No prior chemotherapeutic regimens
  • Prior radiation more than 2 weeks

    • Treatment Plan: ALIMTA will be given as a 10-minute intravenous infusion on day 1 of a 21-day cycle. Cisplatin will be given as a 2-hour intravenous infusion on day 1 of a 21-day cycle.

    ALIMTA and Gemcitabine

    Title: ALIMTA plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A Phase II Clinical Trial

    Eligibility Requirements:

  • Histologically confirmed malignant pleural or peritoneal mesothelioma
  • No prior chemotherapeutic regimens
  • Prior radiation allowed (more than 4 weeks)
  • Prior surgery allowed (more than 4 weeks)

    • Treatment Plan: Folic acid and vitamin B 12 supplements will be given 1-2 weeks prior to chemotherapy administration. Gemcitabine will be given intravenously over 30 minutes on days 1 and 8 of a 21-day cycle. ALIMTA will be given intravenously over 10 minutes on day 8 (prior to gemcitabine) of a 21-day cycle.

  
 

Back to Top